70 related articles for article (PubMed ID: 30736150)
21. Canagliflozin provides durable glycemic improvements and body weight reduction over 104 weeks versus glimepiride in patients with type 2 diabetes on metformin: a randomized, double-blind, phase 3 study.
Leiter LA; Yoon KH; Arias P; Langslet G; Xie J; Balis DA; Millington D; Vercruysse F; Canovatchel W; Meininger G
Diabetes Care; 2015 Mar; 38(3):355-64. PubMed ID: 25205142
[TBL] [Abstract][Full Text] [Related]
22. Glimepiride versus pioglitazone combination therapy in subjects with type 2 diabetes inadequately controlled on metformin monotherapy: results of a randomized clinical trial.
Umpierrez G; Issa M; Vlajnic A
Curr Med Res Opin; 2006 Apr; 22(4):751-9. PubMed ID: 16684436
[TBL] [Abstract][Full Text] [Related]
23. Linagliptin, a dipeptidyl peptidase-4 inhibitor in development for the treatment of type 2 diabetes mellitus: a Phase I, randomized, double-blind, placebo-controlled trial of single and multiple escalating doses in healthy adult male Japanese subjects.
Sarashina A; Sesoko S; Nakashima M; Hayashi N; Taniguchi A; Horie Y; Graefe-Mody EU; Woerle HJ; Dugi KA
Clin Ther; 2010 Jun; 32(6):1188-204. PubMed ID: 20637971
[TBL] [Abstract][Full Text] [Related]
24. Effect of linagliptin compared with glimepiride on postprandial glucose metabolism, islet cell function and vascular function parameters in patients with type 2 diabetes mellitus receiving ongoing metformin treatment.
Forst T; Anastassiadis E; Diessel S; Löffler A; Pfützner A
Diabetes Metab Res Rev; 2014 Oct; 30(7):582-9. PubMed ID: 24459063
[TBL] [Abstract][Full Text] [Related]
25. Influence of type-4 dipeptidyl peptidase inhibition on endothelium-dependent relaxation of aortae from a db/db mouse model of type 2 diabetes: a comparison with the effect of glimepiride.
Woodman OL; Ortega JM; Hart JL; Klein T; Potocnik S
Diabetes Metab Syndr Obes; 2019; 12():1449-1458. PubMed ID: 31496778
[TBL] [Abstract][Full Text] [Related]
26. A safety evaluation of empagliflozin plus linagliptin for treating type 2 diabetes.
Gallwitz B
Expert Opin Drug Saf; 2017 Dec; 16(12):1399-1405. PubMed ID: 28934557
[TBL] [Abstract][Full Text] [Related]
27. Rationale and design of a randomized trial to test the safety and non-inferiority of canagliflozin in patients with diabetes with chronic heart failure: the CANDLE trial.
Tanaka A; Inoue T; Kitakaze M; Oyama J; Sata M; Taguchi I; Shimizu W; Watada H; Tomiyama H; Ako J; Sakata Y; Anzai T; Uematsu M; Suzuki M; Eguchi K; Yamashina A; Saito Y; Sato Y; Ueda S; Murohara T; Node K
Cardiovasc Diabetol; 2016 Apr; 15():57. PubMed ID: 27044332
[TBL] [Abstract][Full Text] [Related]
28. Glucose excursions and hypoglycemia in patients with type 2 diabetes treated with mitiglinide/voglibose versus glimepiride: A randomized cross-over trial.
Fujimoto K; Shibayama Y; Yamaguchi E; Honjo S; Hamasaki A; Hamamoto Y
J Diabetes; 2018 Aug; 10(8):675-682. PubMed ID: 29493100
[TBL] [Abstract][Full Text] [Related]
29. Dipeptidyl peptidase-4 inhibition with linagliptin and effects on hyperglycaemia and albuminuria in patients with type 2 diabetes and renal dysfunction: Rationale and design of the MARLINA-T2D™ trial.
Groop PH; Cooper ME; Perkovic V; Sharma K; Schernthaner G; Haneda M; Hocher B; Gordat M; Cescutti J; Woerle HJ; von Eynatten M
Diab Vasc Dis Res; 2015 Nov; 12(6):455-62. PubMed ID: 26224765
[TBL] [Abstract][Full Text] [Related]
30. Cardiovascular outcome trials in type 2 diabetes and the sulphonylurea controversy: rationale for the active-comparator CAROLINA trial.
Rosenstock J; Marx N; Kahn SE; Zinman B; Kastelein JJ; Lachin JM; Bluhmki E; Patel S; Johansen OE; Woerle HJ
Diab Vasc Dis Res; 2013 Jul; 10(4):289-301. PubMed ID: 23449634
[TBL] [Abstract][Full Text] [Related]
31. Clinical overview of linagliptin, a dipeptidyl peptidase-4 inhibitor, in patients with Type 2 diabetes mellitus.
Forst T; Pfützner A
Expert Rev Endocrinol Metab; 2013 Jan; 8(1):21-35. PubMed ID: 30731650
[TBL] [Abstract][Full Text] [Related]
32. Linagliptin for the treatment of type 2 diabetes mellitus: a drug safety evaluation.
Barnett AH
Expert Opin Drug Saf; 2015 Jan; 14(1):149-59. PubMed ID: 25351273
[TBL] [Abstract][Full Text] [Related]
33. Long-term safety and efficacy of linagliptin as monotherapy or in combination with other oral glucose-lowering agents in 2121 subjects with type 2 diabetes: up to 2 years exposure in 24-week phase III trials followed by a 78-week open-label extension.
Gomis R; Owens DR; Taskinen MR; Del Prato S; Patel S; Pivovarova A; Schlosser A; Woerle HJ
Int J Clin Pract; 2012 Aug; 66(8):731-740. PubMed ID: 22691164
[TBL] [Abstract][Full Text] [Related]
34. Cardiovascular effects of dipeptidyl peptidase-4 inhibitors: from risk factors to clinical outcomes.
Scheen AJ
Postgrad Med; 2013 May; 125(3):7-20. PubMed ID: 23748503
[TBL] [Abstract][Full Text] [Related]
35. Empagliflozin/linagliptin single-pill combination therapy for patients with type 2 diabetes mellitus.
Jain RK
Expert Opin Pharmacother; 2017 Apr; 18(6):545-549. PubMed ID: 28375658
[TBL] [Abstract][Full Text] [Related]
36. Vildagliptin compared to glimepiride on post-prandial lipemia and on insulin resistance in type 2 diabetic patients.
Derosa G; Bonaventura A; Bianchi L; Romano D; Fogari E; D'Angelo A; Maffioli P
Metabolism; 2014 Jul; 63(7):957-67. PubMed ID: 24874591
[TBL] [Abstract][Full Text] [Related]
37. The Effect of Linagliptin versus Metformin Treatment-Related Quality of Life in Patients with Type 2 Diabetes Mellitus.
Mita T; Hiyoshi T; Yoshii H; Chimori H; Ikeda K; Shimizu M; Kojima Y; Yamamto H; Yasuda D; Sato J; Watada H
Diabetes Ther; 2019 Feb; 10(1):119-134. PubMed ID: 30483953
[TBL] [Abstract][Full Text] [Related]
38. Combination of linagliptin and metformin for the treatment of patients with type 2 diabetes.
Haak T
Clin Med Insights Endocrinol Diabetes; 2015; 8():1-6. PubMed ID: 25628514
[TBL] [Abstract][Full Text] [Related]
39. The clinical application of linagliptin in Asians.
Cao CQ; Xiang YF; Zhou ZG
Ther Clin Risk Manag; 2015; 11():1409-19. PubMed ID: 26396526
[TBL] [Abstract][Full Text] [Related]
40. CARdiovascular Outcome study of LINAgliptin versus glimepiride in patients with T2D trial.
Nath B; Suvarna VR
Perspect Clin Res; 2020; 11(1):44-46. PubMed ID: 32154149
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
